Drug intelligence / Profile preview

gabapentin + thiamine + cobalamin

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

Gabapentin + thiamine + cobalamin is a combination drug used primarily for the treatment of neuropathic pain, diabetic neuropathy, nerve damage, and vitamin B deficiencies associated with nerve pain[1][2][4]. **Gabapentin**, a small molecule anticonvulsant, acts as an alpha-2-delta ligand, modulating calcium channel activity and diminishing excitatory neurotransmitter release to reduce pain signaling[2][3][4]. **Thiamine (vitamin B1)** enhances carbohydrate metabolism, suppresses protein glycation and oxidative stress, and improves neuronal energy status[4]. **Cobalamin (vitamin B12, as either cyanocobalamin or methylcobalamin)** supports myelin synthesis, neuronal regeneration, and modulates pain pathways via sensory neuron inhibition and neurotransmitter regulation[4]. B vitamins synergize with gabapentin to enhance pain relief and reduce adverse effects, allowing lower doses of gabapentin for similar efficacy[3][4].

Brand names
Gavindo
Other names
gabapentin + vitamin B1 + vitamin B12gabapentin + thiamine + cyanocobalamingabapentin + benfotiamine + cyanocobalamin
02

Targets

CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (α2δ-2)α2δ (Voltage-gated calcium channel alpha-2-delta subunit)

Beyond the preview

Go deeper on gabapentin + thiamine + cobalamin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gabapentin + thiamine + cobalamin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call